List of Sutab drug patents

Sutab is owned by Braintree Labs.

Sutab contains Magnesium Sulfate; Potassium Chloride; Sodium Sulfate.

Sutab has a total of 3 drug patents out of which 0 drug patents have expired.

Sutab was authorised for market use on 10 November, 2020.

Sutab is available in tablet;oral dosage forms.

Sutab can be used as gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy.

The generics of Sutab are possible to be released after 04 August, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033498 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(14 years from now)

US10143656 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Aug, 2037

(14 years from now)

US11382864 BRAINTREE LABS Solid oral sulfate salt formulations for cleansing a colon and methods of using same
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Nov 10, 2023

Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 10 November, 2020

Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy

Dosage: TABLET;ORAL

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic